TABLE OF CONTENTS
1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET 55
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 58
2 MARKET SEGMENTATION 61
2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 DBMR TRIPOD DATA VALIDATION MODEL 64
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.6 MULTIVARIATE MODELLING 68
2.7 MARKET APPLICATION COVERAGE GRID 69
2.8 TEST TYPE LIFELINE CURVE 70
2.9 DBMR MARKET POSITION GRID 71
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTLE ANALYSIS 78
4.2 PORTER ANALYSIS 79
4.3 EPIDEMIOLOGY 80
5 EUROPE LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 81
6 INDUSTRY INSIGHTS 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 89
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 90
7.1.3 INCREASING CASES OF LIVER CANCER 92
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 93
7.2 RESTRAINTS 95
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 95
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 96
7.3 OPPORTUNITIES 96
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 96
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 96
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 97
7.4 CHALLENGES 98
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 98
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 99
8 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 100
8.1 OVERVIEW 101
8.2 IMAGING TEST 104
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 105
8.2.1.1 MR ANGIOGRAPHY (MRA) 105
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 106
8.2.2 COMPUTED TOMOGRAPHY 106
8.2.3 POSITRON EMISSION TOMOGRAPHY 106
8.2.4 ULTRASOUND 106
8.2.5 OTHERS 106
8.3 GENOMIC TEST 106
8.4 BIOPSY 107
8.4.1 FINE NEEDLE ASPIRATION BIOPSY 108
8.4.2 CORE NEEDLE BIOPSY 108
8.4.3 LAPAROSCOPY 108
8.5 OTHERS 109
9 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 110
9.1 OVERVIEW 111
9.2 STAGE III 114
9.3 STAGE II 115
9.4 STAGE IV 116
9.5 STAGE I 117
9.6 STAGE 0 118
10 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119
10.1 OVERVIEW 120
10.2 SECONDARY LIVER CANCER 123
10.2.1 HEMANGIOMA 124
10.2.2 HEPATIC ADENOMA 124
10.2.3 FOCAL NODULAR HYPERPLASIA 124
10.3 PRIMARY LIVER CANCER 124
10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 125
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 125
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 126
10.3.4 HEPATOBLASTOMA 126
11 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 127
11.1 OVERVIEW 128
11.2 PLATFORM BASED PRODUCTS 131
11.2.1 NEXT GENERATION SEQUENCING 132
11.2.2 MICROARRAYS 132
11.2.3 PCR 132
11.2.4 OTHERS 132
11.3 INSTRUMENT BASED PRODUCTS 132
11.3.1 IMAGING 133
11.3.2 BIOPSY 133
11.4 KITS AND REAGENTS 134
11.4.1 ELISA TEST KITS 135
11.4.2 CASSETTE TEST KITS 135
11.4.3 OTHERS 135
11.5 OTHER CONSUMABLES 135
12 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 136
12.1 OVERVIEW 137
12.2 SCREENING 140
12.2.1 PLATFORM BASED PRODUCTS 141
12.2.2 INSTRUMENT BASED PRODUCTS 141
12.2.3 KITS AND REAGENTS 141
12.2.4 OTHER CONSUMABLES 141
12.3 DIAGNOSTIC AND PREDICTIVE 141
12.3.1 PLATFORM BASED PRODUCTS 142
12.3.2 INSTRUMENT BASED PRODUCTS 142
12.3.3 KITS AND REAGENTS 142
12.3.4 OTHER CONSUMABLES 143
12.4 PROGNOSTIC 143
12.4.1 PLATFORM BASED PRODUCTS 144
12.4.2 INSTRUMENT BASED PRODUCTS 144
12.4.3 KITS AND REAGENTS 144
12.4.4 OTHER CONSUMABLES 144
12.5 RESEARCH 144
12.5.1 PLATFORM BASED PRODUCTS 146
12.5.2 INSTRUMENT BASED PRODUCTS 146
12.5.3 KITS AND REAGENTS 146
12.5.4 OTHER CONSUMABLES 146
13 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 147
13.1 OVERVIEW 148
13.2 FLUORESCENT IN SITU HYBRIDIZATION 151
13.3 NEXT GENERATION SEQUENCING 152
13.4 FLUORIMMUNOASSAY 153
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 154
13.6 IMMUNOHISTOCHEMICAL 155
13.7 OTHERS 156
14 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 157
14.1 OVERVIEW 158
14.2 MALE 161
14.3 FEMALE 162
15 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER 163
15.1 OVERVIEW 164
15.2 HOSPITALS 167
15.3 DIAGNOSTIC CENTERS 168
15.4 CANCER RESEARCH CENTERS 169
15.5 AMBULATORY SURGICAL CENTERS 170
15.6 ACADEMIC INSTITUTES 171
15.7 OTHERS 172
16 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 173
16.1 OVERVIEW 174
16.2 DIRECT TENDER 177
16.3 RETAIL SALES 178
16.4 OTHERS 179
17 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY REGION 180
17.1 EUROPE 181
17.1.1 GERMANY 194
17.1.2 FRANCE 202
17.1.3 RUSSIA 210
17.1.4 ITALY 217
17.1.5 U.K. 225
17.1.6 SPAIN 232
17.1.7 TURKEY 239
17.1.8 NETHERLANDS 246
17.1.9 BELGIUM 254
17.1.10 SWITZERLAND 262
17.1.11 REST OF EUROPE 270
18 EUROPE LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 271
18.1 COMPANY SHARE ANALYSIS: EUROPE 271
19 SWOT ANALYSIS 272
20 COMPANY PROFILE 273
20.1 F. HOFFMANN-LA ROCHE LTD. 273
20.1.1 COMPANY SNAPSHOT 273
20.1.2 REVENUE ANALYSIS 273
20.1.3 COMPANY SHARE ANALYSIS 274
20.1.4 PRODUCT PORTFOLIO 274
20.1.5 RECENT DEVELOPMENT 274
20.2 KONINLIJKE PHILIPS N.V. 275
20.2.1 COMPANY SNAPSHOT 275
20.2.2 REVENUE ANALYSIS 275
20.2.3 COMPANY SHARE ANALYSIS 276
20.2.4 PRODUCT PORTFOLIO 276
20.2.5 RECENT DEVELOPMENT 276
20.3 THERMO FISHER SCIENTIFIC INC. 277
20.3.1 COMPANY SNAPSHOT 277
20.3.2 REVENUE ANALYSIS 277
20.3.3 COMPANY SHARE ANALYSIS 278
20.3.4 PRODUCT PORTFOLIO 278
20.3.5 RECENT DEVELOPMENT 278
20.4 BD 279
20.4.1 COMPANY SNAPSHOT 279
20.4.2 REVENUE ANALYSIS 279
20.4.3 COMPANY SHARE ANALYSIS 280
20.4.4 PRODUCT PORTFOLIO 280
20.4.5 RECENT DEVELOPMENTS 281
20.5 SIEMENS HEALTHCARE GMBH 282
20.5.1 COMPANY SNAPSHOT 282
20.5.2 REVENUE ANALYSIS 282
20.5.3 COMPANY SHARE ANALYSIS 283
20.5.4 PRODUCT PORTFOLIO 283
20.5.5 RECENT DEVELOPMENT 283
20.6 AGILENT TECHNOLOGIES, INC. 284
20.6.1 COMPANY SNAPSHOT 284
20.6.2 REVENUE ANALYSIS 284
20.6.3 PRODUCT PORTFOLIO 285
20.6.4 RECENT DEVELOPMENTS 285
20.7 ABK BIOMEDICAL INC. 286
20.7.1 COMPANY SNAPSHOT 286
20.7.2 PRODUCT PORTFOLIO 286
20.7.3 RECENT DEVELOPMENT 286
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 287
20.8.1 COMPANY SNAPSHOT 287
20.8.2 REVENUE ANALYSIS 287
20.8.3 PRODUCT PORTFOLIO 288
20.8.4 RECENT DEVELOPMENT 288
20.9 ALTOGEN BIOSYSTEMS 289
20.9.1 COMPANY SNAPSHOT 289
20.9.2 PRODUCT PORTFOLIO 289
20.9.3 RECENT DEVELOPMENT 289
20.10 BIOCEPT, INC. 290
20.10.1 COMPANY SNAPSHOT 290
20.10.2 REVENUE ANALYSIS 290
20.10.3 PRODUCT PORTFOLIO 291
20.10.4 RECENT DEVELOPMENT 291
20.11 BODITECH MED INC. 292
20.11.1 COMPANY SNAPSHOT 292
20.11.2 PRODUCT PORTFOLIO 292
20.11.3 RECENT DEVELOPMENTS 292
20.12 DIAGNOSTIC BIOSYSTEMS INC. 293
20.12.1 COMPANY SNAPSHOT 293
20.12.2 PRODUCT PORTFOLIO 293
20.12.3 RECENT DEVELOPMENT 293
20.13 DIAZYME LABORATORIES, INC. 294
20.13.1 COMPANY SNAPSHOT 294
20.13.2 PRODUCT PORTFOLIO 294
20.13.3 RECENT DEVELOPMENT 294
20.14 ELABSCIENCE BIOTECHNOLOGY INC. 295
20.14.1 COMPANY SNAPSHOT 295
20.14.2 PRODUCT PORTFOLIO 295
20.14.3 RECENT DEVELOPMENT 295
20.15 EPIGENOMICS AG 296
20.15.1 COMPANY SNAPSHOT 296
20.15.2 REVENUE ANALYSIS 296
20.15.3 PRODUCT PORTFOLIO 297
20.15.4 RECENT DEVELOPMENT 297
20.16 FUJIFILM CORPORATION 298
20.16.1 COMPANY SNAPSHOT 298
20.16.2 REVENUE ANALYSIS 298
20.16.3 PRODUCT PORTFOLIO 299
20.16.4 RECENT DEVELOPMENT 299
20.17 FUJIREBIO 300
20.17.1 COMPANY SNAPSHOT 300
20.17.2 PRODUCT PORTFOLIO 300
20.17.3 RECENT DEVELOPMENTS 300
20.18 HIPRO BIOTECHNOLOGY CO., LTD. 301
20.18.1 COMPANY SNAPSHOT 301
20.18.2 PRODUCT PORTFOLIO 301
20.18.3 RECENT DEVELOPMENT 301
20.19 ILLUMINA, INC. 302
20.19.1 COMPANY SNAPSHOT 302
20.19.2 REVENUE ANALYSIS 302
20.19.3 PRODUCT PORTFOLIO 303
20.19.4 RECENT DEVELOPMENTS 304
20.20 MOLGEN 305
20.20.1 COMPANY SNAPSHOT 305
20.20.2 PRODUCT PORTFOLIO 305
20.20.3 RECENT DEVELOPMENT 305

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.